Recent Updates
Recently added Catalysts
CRMD Positive Sentiment

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

Wednesday, July 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CorMedix Therapeutics will announce its second quarter financial results on August 13, 2026, before market opening. The company will also conduct a corporate update conference call at 8:30 AM ET. CorMedix is dedicated to developing therapeutic products for serious health conditions in the U.S.
Price reaction · baseline $7.35 (2026-07-28 close) · hit pre-market · clean, no other CRMD news in the window
day 0 close · peak
-2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • CorMedix is actively engaging with investors through a corporate update.
  • The company is focused on developing products for life-threatening conditions.
  • Scheduled financial results indicate transparency and accountability.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
25.7%
average across 3 past catalysts
Lead asset
Single-Dose Oritavancin Diphosphate
Phase 1 · Healthy

Full Press Release Details

PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
Thursday, August 13 th @ 8:30am ET
Domestic: 1-844-676-2922
International: 1-412-634-6840
Webcast: Webcast Link
About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.

Investor Contact: Dan Ferry Managing Director LifeSci Advisors daniel@lifesciadvisors.com (617) 430-7576

Frequently Asked Questions

When will CorMedix report its Q2 2026 financial results?

CorMedix will report its Q2 2026 financial results on August 13, 2026.

What time is the corporate update conference call?

The corporate update conference call is scheduled for 8:30 AM Eastern Time.

What is the focus of CorMedix Therapeutics?

CorMedix focuses on developing therapeutic products for life-threatening conditions.

How can investors contact CorMedix?

Investors can contact Dan Ferry at LifeSci Advisors for inquiries.

ShareAdd on Google
Tags: CRMD CorMedix financial results corporate update biopharmaceuticals
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$257M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Single-Dose Oritavancin DiphosphatePhase 1
Healthy →

Catalyst track record

+12%
best trade around CRMD's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for CRMD.

See every catalyst's timing & PoA →